454 related articles for article (PubMed ID: 26209900)
1. Management of Hypereosinophilic Syndromes.
Roufosse F
Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
[TBL] [Abstract][Full Text] [Related]
2. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Borbényi Z
Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
[TBL] [Abstract][Full Text] [Related]
3. [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].
Green L; Kahn JE; Dufour JF; Le Scanff J; Charhon A; Broussolle C; Sève P
Rev Med Interne; 2010 Apr; 31(4):305-8. PubMed ID: 20167399
[TBL] [Abstract][Full Text] [Related]
4. Imatinib for the treatment of hypereosinophilic syndromes.
Helbig G
Expert Rev Clin Immunol; 2018 Feb; 14(2):163-170. PubMed ID: 29303368
[TBL] [Abstract][Full Text] [Related]
5. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
6. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
[TBL] [Abstract][Full Text] [Related]
7. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S
Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910
[No Abstract] [Full Text] [Related]
8. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
Iurlo A; Cattaneo D; Gianelli U
Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
[No Abstract] [Full Text] [Related]
9. Clinical management of the hypereosinophilic syndromes.
Cogan E; Roufosse F
Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
[TBL] [Abstract][Full Text] [Related]
10. Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome.
Weyand AC; Yanik GA; Bailey NG; Wu YM; Mody RJ; Castle VP
Pediatr Blood Cancer; 2016 Jan; 63(1):164-7. PubMed ID: 26257279
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
Menif S; Ben Romdhane N; Hafsia R
Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M
Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901
[No Abstract] [Full Text] [Related]
13. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).
von Bubnoff N; Gorantla SP; Thöne S; Peschel C; Duyster J
Blood; 2006 Jun; 107(12):4970-1; author reply 4972. PubMed ID: 16754777
[No Abstract] [Full Text] [Related]
14. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia.
Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE
Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057
[No Abstract] [Full Text] [Related]
15. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU; Bochner BS; Butterfield JH; Gleich GJ; Huss-Marp J; Kahn JE; Leiferman KM; Nutman TB; Pfab F; Ring J; Rothenberg ME; Roufosse F; Sajous MH; Sheikh J; Simon D; Simon HU; Stein ML; Wardlaw A; Weller PF; Klion AD
J Allergy Clin Immunol; 2009 Dec; 124(6):1319-25.e3. PubMed ID: 19910029
[TBL] [Abstract][Full Text] [Related]
16. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene.
García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM
Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041
[No Abstract] [Full Text] [Related]
17. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J
Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294
[No Abstract] [Full Text] [Related]
18. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.
Helbig G; Kyrcz-Krzemień S
Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127
[No Abstract] [Full Text] [Related]
19. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
20. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib.
Kobayashi M; Kubota T; Uemura Y; Taguchi H
Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]